(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
-6.74% CHF 3.18
Live Chart Being Loaded With Signals
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding...
Stats | |
---|---|
Volumen de hoy | 550 055 |
Volumen promedio | 776 085 |
Capitalización de mercado | 315.45M |
EPS | CHF0 ( 2024-05-17 ) |
Próxima fecha de ganancias | ( CHF-0.150 ) 2024-06-21 |
Last Dividend | CHF0 ( N/A ) |
Next Dividend | CHF0 ( N/A ) |
P/E | -4.54 |
ATR14 | CHF0.0130 (0.41%) |
Volumen Correlación
AC Immune SA Correlación
10 Correlaciones Más Positivas | |
---|---|
ADPT | 0.896 |
ASTS | 0.889 |
WKHS | 0.888 |
NEOG | 0.881 |
SCPH | 0.881 |
SOPA | 0.881 |
AEHR | 0.88 |
OM | 0.88 |
ALTM | 0.877 |
BCDA | 0.876 |
10 Correlaciones Más Negativas | |
---|---|
KRUS | -0.862 |
MASI | -0.835 |
SFBC | -0.828 |
ADTH | -0.827 |
KINS | -0.822 |
INBKZ | -0.819 |
EDAP | -0.818 |
EDUC | -0.815 |
LPCN | -0.812 |
TAYD | -0.81 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
AC Immune SA Correlación - Moneda/Commodity
AC Immune SA Finanzas
Annual | 2023 |
Ingresos: | CHF14.80M |
Beneficio Bruto: | CHF-39.81M (-268.93 %) |
EPS: | CHF-0.640 |
FY | 2023 |
Ingresos: | CHF14.80M |
Beneficio Bruto: | CHF-39.81M (-268.93 %) |
EPS: | CHF-0.640 |
FY | 2022 |
Ingresos: | CHF3.94M |
Beneficio Bruto: | CHF-56.40M (-1 433.32 %) |
EPS: | CHF-0.850 |
FY | 2021 |
Ingresos: | CHF0.00 |
Beneficio Bruto: | CHF0.00 (0.00 %) |
EPS: | CHF-0.970 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico